FDA Orange Book
Is there a generic for Zepbound Kwikpen?
Zepbound Kwikpen contains tirzepatide. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Zepbound Kwikpen (tirzepatide). The Orange Book shows its last listed patent expires July 22, 2039 and its last listed exclusivity ends December 20, 2027.
Run it in Rivvi
Map Zepbound Kwikpen and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Zepbound Kwikpen products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, subcutaneous | 10MG/2.4ML (4.17MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 20MG/2.4ML (8.33MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 30MG/2.4ML (12.5MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 40MG/2.4ML (16.7MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 50MG/2.4ML (20.8MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 60MG/2.4ML (25MG/ML) | Marketed (Rx) | None | 0 | None |
NDA 217806, held by ELI LILLY AND CO. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Zepbound Kwikpen patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 9474780 | May 13, 2036 | Drug substance, Drug product | None | 217806 |
| 12343382 | July 22, 2039 | Method of use | U-4228 | 217806 |
| 12343382 | July 22, 2039 | Method of use | U-4227 | 217806 |
| 12343382 | July 22, 2039 | Method of use | U-4410 | 217806 |
| 12343382 | July 22, 2039 | Method of use | U-4409 | 217806 |
| 12453758 | July 22, 2039 | Method of use | U-4310 | 217806 |
| 12453758 | July 22, 2039 | Method of use | U-4309 | 217806 |
| 12453758 | July 22, 2039 | Method of use | U-4308 | 217806 |
| 12453758 | July 22, 2039 | Method of use | U-4311 | 217806 |
| 12616740 | July 22, 2039 | Method of use | U-4497 | 217806 |
| 12616740 | July 22, 2039 | Method of use | U-4498 | 217806 |
| 12616740 | July 22, 2039 | Method of use | U-4499 | 217806 |
Zepbound Kwikpen exclusivity
| Code | Meaning | Expires | NDA |
|---|---|---|---|
| NCE | New chemical entity | May 13, 2027 | 217806 |
| M-82 | Miscellaneous | October 18, 2027 | 217806 |
| I-958 | New indication | December 20, 2027 | 217806 |
Zepbound Kwikpen NDC codes
Questions
Is there a generic for Zepbound Kwikpen?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Zepbound Kwikpen (tirzepatide). The Orange Book shows its last listed patent expires July 22, 2039 and its last listed exclusivity ends December 20, 2027.
What is the generic name for Zepbound Kwikpen?
The active ingredient in Zepbound Kwikpen is tirzepatide, per the FDA Orange Book.
When does the Zepbound Kwikpen patent expire?
The last patent listed for Zepbound Kwikpen in the Orange Book expires July 22, 2039. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.